Assertio (ASRT) Q4 2024 earnings summary

Executive summary

• 2024 marked a stabilization year, transitioning from Indocin to Rolvedon as the lead asset after the Spectrum acquisition and Indocin's loss of exclusivity.

• Rolvedon sales exceeded $60 million, with growth in community oncology clinics, while Indocin managed erosion from generic competition.

• The company optimized its portfolio, generated over $26 million in operating cash flow, and strengthened its balance sheet to support transformation in 2025.

• Leadership changes included new appointments in commercial and transformation roles, and additions to the board with significant industry experience.

• Focus for 2025 includes driving revenue growth in Rolvedon and Sympazan, managing legal exposure, and pursuing acquisitions.

Financial highlights

• Q4 product sales reached $29.6 million, up from $28.7 million in Q3; full-year product sales were $120.8 million, down from $149.5 million in 2023.

• Rolvedon Q4 sales were $15.4 million, up $0.4 million sequentially; Indocin sales were $5.5 million, slightly down due to pricing pressure.

• Q4 gross margin was 61%, down from 74% in Q3 due to $2.9 million in Indocin inventory write-downs; excluding charges, gross margin was 71%.

• Q4 GAAP net loss was $10.5 million, impacted by a $5.2 million intangible asset impairment; adjusted EBITDA was a loss of $0.5 million.

• Cash and investments at year-end totaled $100.1 million; debt was $40.0 million with no maturities until September 2027.

• Operating cash flow for 2024 was $26.4 million, exceeding the high-end cash goal.

Outlook and guidance

• 2025 is positioned as a year of transformation, focusing on simplifying structure, growing Rolvedon and Sympazan, reducing legal exposure, and deploying capital for value creation.

• Net sales guidance for 2025 is $108–123 million; adjusted EBITDA guidance is $10–19 million.

• Modest Rolvedon growth and double-digit Sympazan growth expected, offset by continued Indocin decline and flat-to-slightly declining rest of portfolio.

• Q1 2025 Rolvedon sales expected to be lower than Q4 2024, with Q2 growth anticipated.

• Strategic options, including potential acquisitions, are under evaluation and could impact future guidance.